Effectiveness of Trolamine in Preventing Radiotherapy-Related Skin Toxicity in Breast Cancer: A Meta-Analysis and Trial Sequential Analysis Study of Randomized Controlled Trials.

IF 1.5 4区医学 Q3 DERMATOLOGY

Advances in Skin & Wound Care Pub Date : 2026-09-01 Epub Date: 2026-06-09 DOI:10.1097/ASW.0000000000000487

Lufeng Xie, Yu Zeng, Binbin Zhang, Xiaoli Yuan

{"title":"Effectiveness of Trolamine in Preventing Radiotherapy-Related Skin Toxicity in Breast Cancer: A Meta-Analysis and Trial Sequential Analysis Study of Randomized Controlled Trials.","authors":"Lufeng Xie, Yu Zeng, Binbin Zhang, Xiaoli Yuan","doi":"10.1097/ASW.0000000000000487","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy of trolamine in preventing radiotherapy-associated skin toxicity in patients with breast cancer.Data sources: PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Database, and Chinese Biomedical Literature Database (CBM).Study selection: The included randomized controlled trials focused on the incidence of grade 0 to 1 cutaneous toxicity, the incidence of grade 2 cutaneous toxicity, the incidence of grade 2 or higher cutaneous toxicity, and the incidence of grade 3 or higher cutaneous toxicity.Data extraction: Data on participant demographics, intervention details, and outcome measures were collected from the selected studies.Data synthesis: A total of 10 randomized controlled trials involving 980 patients with breast cancer were included. Results showed that the incidence of grade 0 to 1 skin toxicity was significantly higher in the trolamine group (RR = 1.89; 95% CI [1.05, 3.40]; P = .03), whereas the incidence of grade 2 (RR = 0.51; 95% CI [0.27, 0.96]; P = .04), grade 2 or higher (RR = 0.52; 95% CI [0.31, 0.87]; P = .01), and grade 3 or higher (RR = 0.37; 95% CI [0.23, 0.62]; P = .0001) skin toxicity was significantly lower. Based on the GRADE approach, the quality of evidence was rated as \"low\" for grades 0 to 1, grade 2, and grade 2 or higher skin toxicity, whereas evidence for grade 3 or higher skin toxicity was rated as \"moderate.\"Conclusions: Trolamine significantly reduces the incidence of grade 2 and higher skin toxicity, particularly grade 3 or higher skin toxicity.","PeriodicalId":7489,"journal":{"name":"Advances in Skin & Wound Care","volume":" ","pages":"429-439"},"PeriodicalIF":1.5000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Skin & Wound Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ASW.0000000000000487","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy of trolamine in preventing radiotherapy-associated skin toxicity in patients with breast cancer.

Data sources: PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Database, and Chinese Biomedical Literature Database (CBM).

Study selection: The included randomized controlled trials focused on the incidence of grade 0 to 1 cutaneous toxicity, the incidence of grade 2 cutaneous toxicity, the incidence of grade 2 or higher cutaneous toxicity, and the incidence of grade 3 or higher cutaneous toxicity.

Data extraction: Data on participant demographics, intervention details, and outcome measures were collected from the selected studies.

Data synthesis: A total of 10 randomized controlled trials involving 980 patients with breast cancer were included. Results showed that the incidence of grade 0 to 1 skin toxicity was significantly higher in the trolamine group (RR = 1.89; 95% CI [1.05, 3.40]; P = .03), whereas the incidence of grade 2 (RR = 0.51; 95% CI [0.27, 0.96]; P = .04), grade 2 or higher (RR = 0.52; 95% CI [0.31, 0.87]; P = .01), and grade 3 or higher (RR = 0.37; 95% CI [0.23, 0.62]; P = .0001) skin toxicity was significantly lower. Based on the GRADE approach, the quality of evidence was rated as "low" for grades 0 to 1, grade 2, and grade 2 or higher skin toxicity, whereas evidence for grade 3 or higher skin toxicity was rated as "moderate."

Conclusions: Trolamine significantly reduces the incidence of grade 2 and higher skin toxicity, particularly grade 3 or higher skin toxicity.

查看原文本刊更多论文

三硝胺预防乳腺癌放疗相关皮肤毒性的有效性：随机对照试验的荟萃分析和试验序贯分析研究。

目的：评价三硝胺预防乳腺癌患者放疗相关皮肤毒性的疗效。数据来源：PubMed、Embase、Cochrane Library、Web of Science、ClinicalTrials.gov、中国知网、万方数据、VIP数据库、中国生物医学文献数据库（CBM）。研究选择：纳入的随机对照试验侧重于0至1级皮肤毒性的发生率，2级皮肤毒性的发生率，2级或更高级别皮肤毒性的发生率，以及3级或更高级别皮肤毒性的发生率。数据提取：从选定的研究中收集有关参与者人口统计、干预细节和结果测量的数据。资料综合：共纳入10项随机对照试验，涉及980例乳腺癌患者。结果显示，三甲胺组0 ~ 1级皮肤毒性发生率显著高于对照组（RR = 1.89, 95% CI [1.05, 3.40], P = 0.03），而2级（RR = 0.51, 95% CI [0.27, 0.96], P = 0.04）、2级及以上（RR = 0.52, 95% CI [0.31, 0.87], P = 0.01）、3级及以上（RR = 0.37, 95% CI [0.23, 0.62], P = 0.0001）皮肤毒性发生率显著低于对照组（RR = 0.37, 95% CI [0.23, 0.62], P = 0.0001）。根据GRADE方法，0至1级、2级和2级或更高皮肤毒性的证据质量被评为“低”，而3级或更高皮肤毒性的证据被评为“中等”。结论：Trolamine可显著降低2级及以上皮肤毒性的发生率，特别是3级及以上皮肤毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Skin & Wound Care DERMATOLOGY-NURSING

CiteScore

2.50

自引率

12.50%

发文量

271

审稿时长

>12 weeks

期刊介绍： A peer-reviewed, multidisciplinary journal, Advances in Skin & Wound Care is highly regarded for its unique balance of cutting-edge original research and practical clinical management articles on wounds and other problems of skin integrity. Each issue features CME/CE for physicians and nurses, the first journal in the field to regularly offer continuing education for both disciplines.